Allergy

As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Research suggests wildfire smoke does more than irritate the airways in the moment; it may worsen allergic disease for months afterward.

Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.

The FDA granted lonvo-z priority review for HAE, setting a PDUFA date of March 10, 2027 based on positive Phase 3 HAELO data.

Alpha-gal syndrome remains vastly underdiagnosed, with expanding tick geography and delayed reactions complicating recognition across specialties.

FDA actions, a WAO consensus update, and late-stage trial data in food allergy, anaphylaxis, CRSwNP, and EoE, all in this August 2026 recap.

Mahboobeh Mahdavinia, MD, says a published, safe at-home protocol for resolving egg allergy is rarely used because of the counseling time it demands.

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

The Phase 3 CROSSING trial showed tezepelumab improved histologic remission and dysphagia symptoms through week 52 in eosinophilic esophagitis.

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.

An international 35-expert Delphi panel reached consensus on 33 of 35 statements on precautionary allergen labelling reference doses.

A FORWARD cohort study of 1,359 children found race, income, health literacy, and neighborhood deprivation each predicted food allergy resolution.

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.

Lieberman discusses atypical anaphylaxis signs in infants and toddlers and why epinephrine remains underused.